CMMB — Chemomab Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $0.53m
- -$19.26m
Annual balance sheet for Chemomab Therapeutics, fiscal year end - December 31st, millions except per share.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-Q | 10-K | 10-K | 20-F | |
| Standards: | — | USG | USG | USG | USG |
| Status: | fx Preliminary | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | — | 11.7 | 61.2 | 39.9 | 19.8 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | — | 11.8 | 62.7 | 41.7 | 20.9 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 0.58 | 0.702 | 0.594 | 0.695 |
| Other Long Term Assets | |||||
| Total Assets | — | 12.5 | 64.4 | 43.1 | 22.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | — | 1.32 | 2.65 | 6.75 | 4.84 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | — | 1.67 | 2.89 | 6.84 | 5.15 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | — | 10.8 | 61.5 | 36.2 | 17 |
| Total Liabilities & Shareholders' Equity | — | 12.5 | 64.4 | 43.1 | 22.2 |
| Total Common Shares Outstanding |